Human Phenotype Ontology Back Human Phenotype Ontology Research Partner In 2022, the Monarch Initiative signed a five-year collaboration agreement with SNOMED International to develop maps from the clinical terminology SNOMED CT to Human Phenotype Ontology (HPO), a standardized vocabulary of phenotypic abnormalities encountered in human disease, and to HPO from SNOMED CT. Additional information HPO is a flagship product of the Monarch Initiative , a US National Institutes of Health -supported international consortium dedicated to semantic integration of biomedical and model organism data with the ultimate goal of improving biomedical research, and an integrative data and analytic platform connecting phenotypes to genotypes across species, bridging basic and applied research with semantics-based analysis. It is also a central component of one of the 13 driver projects in the Global Alliance for Genomics and Health strategic roadmap. As part of the agreement, the organizations will work together to develop mapping conventions by which both maps will be created, along with use cases. Both organizations will also collaborate on quality assurance, promoting the maps to their respective stakeholders and defining and agreeing upon an ongoing maintenance and updating process and policy for the developed maps. Press Release: February 2023: SNOMED and the Monarch Initiative collaborate to develop two-way maps for HPO Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

A dedicated terminology to support the International Patient Summary Back 5 May 2022 Back Since the date of issue, this information is now out of date and has been archived. It has been made available for reference. Towards the end of 2021, SNOMED International shared its intention to extend the core of SNOMED CT’s structured clinical terminology to deliver an open, standalone terminology in support of the scope of content within the International Patient Summary (IPS) for non-Members. The IPS is an electronic health record extract containing essential healthcare information for use in circumstances where citizens may travel from their home country and require unscheduled and unanticipated health care from a different jurisdiction, as well as for local, regional and other care scenarios. It is a minimal, non-exhaustive set of data elements defined by ISO/EN 17269 and delivered by HL7 in both CDA and FHIR using a curated set of SNOMED CT terms. Readily usable by clinicians, the primary use case for the IPS is to support cross-border and unscheduled patient care. However, it also has the potential to be used in many other scenarios where a patient crosses health information systems, such as travel between provinces/states, cities or organizations that use a different Health Information System and require a summary for immediate care. Since 2019, and predating the Organization’s IPS Terminology initiative, SNOMED International has made a free set of SNOMED CT codes available (the HL7 IPS free set), as part of its Global Patient Set (GPS) to support the implementation of the HL7 FHIR IPS specification . With a scope that differs from the GPS, a flat list of SNOMED CT codes and terms without hierarchy or relationships, the IPS Terminology will provide implementers with a product that can be used in healthcare solutions using the power of SNOMED CT through its query language and hierarchies for the specified scope of the IPS. The IPS Terminology is the next evolution of the HL7 IPS free set, providing advanced terminology features for non-Affiliates to use in their IPS implementations. In the first months of 2022, SNOMED International has been configuring its approach to making the IPS Terminology a tangible artifact in its lineup of SNOMED CT-driven products and services. Released in its beta version for focused stakeholder testing and feedback, the IPS Terminology will be accompanied by a User Guide to aid implementers in non-Member regions in their understanding of the features, capabilities, and limitations of the IPS Terminology package. Providing an overview of the IPS Terminology's scope and features, the Guide will also provide IPS Terminology use cases as well as direction on how to implement the IPS Terminology in a terminology server, and on how to upgrade to a full SNOMED CT edition if additional terminology content is required. It is worth noting that current SNOMED CT users, those located in a SNOMED International Member region or those with an Affiliate license to a complete SNOMED CT edition, should avoid use of the IPS Terminology and instead, implement their IPS solutions using a full edition of SNOMED CT. To share IPS data with non-Affiliates, licensed users may choose to refer to the IPS Reference Set. This reference set identifies the subset of key concepts from the IPS Terminology and is available as a supplementary package from SNOMED International's MLDS service . Contact releases@snomed.org for information on how to review the IPS Terminology as well as information on the mechanisms and timelines for providing feedback. To view the IPS Terminology via browser, visit https://ips-browser.snomedtools.org/ . Subscribe to the Organization’s news service to learn more as this initiative progresses. For additional information, contact info@snomed.org . Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

SNOMED International is welcoming two new directors to its Management Board. New SNOMED International Management Board directors offer abundance of international leadership experience SNOMED International is welcoming two new directors to its Management Board. Back 23 Feb 2023 Back London, United Kingdom – SNOMED International is welcoming two new directors to its Management Board. The organization’s Management Board is a governance body with legal and oversight responsibility for the management and direction of SNOMED International. It offers the organization a wealth of experience in global healthcare and informatics, advanced technologies, organizational governance and business leadership and risk management, guiding us as we execute against our strategy and plan for the future. Management Board directors’ expertise and industry relationships are key to helping SNOMED International leverage technologies and strengthen partnerships with our many stakeholders worldwide, and guide the organization on the development and execution of our current five-year strategy . Anne-Marie Grey brings more than 30 years of humanitarian fundraising and marketing experience, both in the United States and internationally to SNOMED International. The recent Executive Director and CEO for USA for UNHCR , Anne-Marie is the Principal Director at New York-based Grey-O’Keefe Consulting LLC , a training, strategy, and marketing agency that brings causes and corporations together to positively impact society and business. She brings to the Board her unique and extensive leadership skills in both the not-for-profit and private sectors. Anne-Marie has mentored and advised non-profit leaders on resource mobilization, leadership and strategy at organizations such as the Forbes Nonprofit Council , an invitation-only, fee-based organization for senior-level executives in successful nonprofit organizations; USA for UNHCR ; UNHCR ; Save the Children ; and UNICEF . In addition to an educational background in art history, literature, finance and non-profit management, Anne-Marie has obtained DiSC and Five Behaviors partner certification, and is a Certified Professional Co-Active Coach and International Coaching Federation credential trained coach, facilitator, author, and international speaker. Bersabel Ephrem brings to the Management Board 32 years of experience in the areas of leadership, governance and public health policy and program management and has worked in several organizations within the Canadian Federal Government. Most recently, she served as the Director General of Centre of Communicable Diseases and Infection Control within the Public Health Agency of Canada . Prior to that, Bersabel served as the Senior Advisor to the Director General of the World Health Organization on management reform, where she provided leadership and oversight in the development of policies and institutionalized key governance initiatives. Bersabel has also served as Director General at the International Affairs Division of Health Canada . In this role, Bersabel led the Canadian delegation on several groundbreaking negotiations in WHO and the Pan American Health Organization. Her international experience includes serving as the Chair of APEC Health Task Force, head of the Secretariat for the Global Health Security Initiative and as the Vice Chair of the Board of Members at the Global Antimicrobial Resistance (AMR) Research and Development Hub , providing her with unique insights on the challenges global healthcare-focused organizations must navigate and on successful strategies to advance on their goals. The breadth of skills possessed by the organization’s new and existing Management Board representatives are highly relevant to SNOMED International’s global membership structure and to the organization’s work developing SNOMED CT, a global terminology working to become the “one language of health” worldwide. Joanne Burns, Chair of the Management Board since 2020, remarks on the importance of bringing together a group of individuals with a variety of perspectives and experience from across this organization’s many valued stakeholder groups. “Ms. Grey’s and Ms. Ephrem’s depth of experience and skills honed across multiple national and international organizations and sectors over many years will contribute significantly to the strategy, finance and risk acumen of the SNOMED International Management Board.” SNOMED International CEO Don Sweete concurs. “Each of our new Management Board directors offers a suite of diverse strengths and highly relevant in-depth knowledge that will help move the organization forward,” he said. “I look forward to the positive impact they will have as they settle in and become integrated into the current Board.” Ms. Grey and Ms. Ephrem, both appointed to a two-year term, join a strong group of six Management Board Directors: Joanne Burns, Chair; and Directors Dr. Matic Meglic; Dr. Gong Mengchun; Dr. Isabelle de Zegher; Professor Michael Lewis; and Dr. Andrew Roddam. Learn more about the SNOMED International Management Board. Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

WHO explores collaboration with SNOMED International for linkage between ICD-11 and SNOMED CT Back 22 Oct 2024 Back WHO and SNOMED International are presently exploring a joint sustainable framework to link ICD-11 and SNOMED CT. The World Health Organization (WHO) collaborates with various standards-developing organizations to enhance the interoperability of international health information systems. The linkage of the International Classification of Diseases 11th revision (ICD-11) with other terminologies has been a part of WHO's strategic plan since 2001. This collaboration aims to facilitate a seamless data conversion and linkages for users of both ICD-11 and SNOMED CT towards a robust and interoperable health data ecosystem. This will enable the usability of health information across diverse applications, improving data consistency and usability for the software industry; data brokers; clinical, statistical and epidemiological research; and reimbursement purposes. This collaborative effort aligns with WHO’s mandate to facilitate the connection between its core classification systems and terminologies with other terminologies, enabling more efficient health data exchange worldwide. “WHO envisions a world where health systems speak a common language. We are committed to fostering interoperability and advancing universal health coverage. We value collaboration with SNOMED International and other partners to support Member States in building robust digital health systems. Linking ICD-11 and SNOMED CT will enable the effective use of health data – ultimately saving lives,” said Samira Asma, Assistant Director-General for Data, Analytics and Delivery for Impact at WHO. SNOMED International CEO, Don Sweete, is encouraged by the developing and collaborative work that has been progressed by the WHO and SNOMED International organizations for the overall benefit of their joint users globally. "SNOMED and WHO Members alike are searching for seamless solutions that serve the digital health information management needs of policy makers, clinicians, informaticians and citizens as it relates to the use of both ICD-11 and SNOMED CT. I am encouraged by the commitment both organizations have taken to serve this need, jointly exploring the range of pragmatic and accelerated approaches available." For more information on this planned collaboration, please contact SNOMED International ( info@snomed.org ) or WHO ( icd@who.int ). Other contacts : WHO: mediainquiries@who.int SNOMED International: comms@snomed.org Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

BLOG: Exploring a move from PCOS to PMOS Back 2 Jun 2026 Back In this Q&A blog post, SNOMED International Chief Terminologist Dr James Case discusses SNOMED International’s response to the current international efforts to rename Polycystic ovary syndrome (PCOS), a common hormonal disorder that affects reproductive-aged women that is characterized by an imbalance of reproductive hormones and high levels of androgens, to Polyendocrine metabolic ovarian syndrome (PMOS), which better reflects its complexity. He also explores the options being considered and the timelines and process of renaming the term in SNOMED CT, and, importantly, explains how a terminology change would improve the experience and treatment of patients with the condition. Q: There is a strong international push to rename PCOS to PMOS. Can you explain the meaning of each and the argument behind the name change? A: Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), affects approximately one in eight women, although the true prevalence is likely higher due to underdiagnosis. The name change reflects the recognition that the condition is a complex multisystem endocrine and metabolic disorder rather than primarily an ovarian disorder. Diagnosis requires two of three features: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries on ultrasound or elevated anti-Müllerian hormone. The new name also addresses a long-standing source of confusion between a clinical syndrome and an anatomical finding. Polycystic ovaries are a common finding and, by themselves, do not constitute the syndrome. By shifting the focus away from ovarian morphology, PMOS more accurately reflects the underlying disease process while clearly distinguishing the syndrome from the separate finding of polycystic ovaries. Q: How would a change in terminology contribute to better patient care and a better experience for patients? A: A change in terminology can improve patient care by reducing misconceptions about the condition and promoting a more accurate understanding of its underlying causes. Polycystic ovaries are neither required for nor sufficient to diagnose the syndrome, yet the name Polycystic ovary syndrome can imply otherwise. Renaming the condition to Polyendocrine metabolic ovarian syndrome (PMOS) better reflects its endocrine and metabolic nature, helping patients and clinicians focus on the broader health implications of the disorder. This may support earlier recognition, more comprehensive evaluation, and better long-term management. Q: In your post to the community, you asked for feedback on whether they agree with the name change, and you outlined the options going forward. Can you share your thoughts on how SNOMED’s editorial policy supports the change and why and whether it should or should not be changed? A: SNOMED strives to provide the most up-to-date representation of clinical disorders; however, in many cases there is a long lag before new terminology becomes common usage in the clinical community. We frequently use international consensus publications as the justification for name changes, but we do not make those changes until we have reasonable evidence that it would be acceptable to the clinical community. A recent example was the change of the name of Diabetes insipidus to Arginine vasopressin-related polyuria. We worked with a number of endocrinologists who socialized that name change with their community prior to SNOMED making the changes. In this case, for PMOS, the consensus process was extremely robust and there has been a substantial amount of positive coverage, both in the medical literature and the lay press. SNOMED agrees with the change as it more accurately represents the nature of the condition, but wants to ensure that adopting the name at this early stage is not disruptive to the community as it requires replacement of the old concept with a new one rather than just changing the name. Q: Can you outline the various potential approaches for the future that you proposed and the pros and cons of each? A: The three possible approaches (there may be others) are: No change yet — monitor usage of the term in the literature and adoption by other terminology standards, (such as ICD) before acting. This would be more retroactive than proactive, but would be in line with the adoption strategy described in the Lancet article, in which integration with SNOMED does not occur until Step 4, after broad academic dissemination and global communication. Add PMOS as a synonym now — with preferred term status and with replacement deferred to a defined milestone such as ICD adoption or the 2028 International Guidelines update. This would make the new name available immediately without affecting existing implementations, but would not represent the new definitional characteristics, which does not correct the mischaracterization of the disorder as primarily a cystic condition. Inactivate the existing concept and create a new PMOS concept — the editorially rigorous path, with PCOS description added as a historical synonym and appropriate replacement associations provided for implementers. The advantage to this approach is that it is a more accurate representation of the condition and retains the older term for searchability, but it impacts historical data by requiring the use of a new concept, affecting implementations. It would also require the use of historical relationships in queries to retrieve old data, making analytics more complex. Q: What would be the timelines for each of the approaches? A: The first option of waiting for more evidence of adoption could delay the renaming for 1-2 years, while options 2 and 3 could be implemented in SNOMED CT very quickly (weeks to months). Q: You also asked the community for feedback on these questions: Does the robustness of this consensus process justify early action in SNOMED CT? Which approach best balances editorial integrity, implementer impact, and patient benefit? What milestone should trigger full adoption if a deferred approach is preferred? Should PCOS be retained indefinitely as an acceptable synonym or deprecated over the transition period? What is the timeline for feedback and what are the next steps? Will you be conducting any further consultations or will you move forward based on the feedback you get? A: We are estimating a 60-day comment period to ensure everyone has an opportunity to respond; however, if we receive overwhelming support for one option, we will adopt that one sooner. We are also reaching out to the authors of the Lancet paper to get their views on including the new name in SNOMED CT in light of their adoption strategy. We do not anticipate additional consultations as we expect a substantial number of responses given the amount of exposure that this topic has been given. To provide feedback, please visit our Forums page .The feedback window is open until July 18, 2026. Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

International League Against Epilepsy Back International League Against Epilepsy Clinical Partner In 2022, SNOMED International and the International League Against Epilepsy (ILAE) signed a five-year agreement to contribute global improvements in care and services for people with epilepsy, a group of disorders characterized by recurrent seizures. The ILAE Commission for Big Data and SNOMED International have established an Epilepsy Clinical Project Group . Members of this group will work together to define processes to maintain and update epilepsy content within the international edition of SNOMED CT’s clinical terminology, the world’s most comprehensive healthcare terminology product. Additional information Over 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Although about two-thirds of people with epilepsy could be seizure free with medication treatment, gaps in diagnosis and treatment mean that millions of people continue to have seizures, which affect their health, relationships, education, and employment opportunities. The SNOMED CT International Edition has included epilepsy content for many years; now, users will benefit from input from global experts in a systematic way to ensure that the content is up to date and out of date epilepsy terminology is retired. Press release: September 2022: Collaboration agreement between SNOMED International and the International League Against Epilepsy will raise the clinical quality of global epilepsy terminology Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

Position Statement: SNOMED CT Pharmaceutical Product Concept Model and Content Back 13 Apr 2017 Back A key emerging theme globally is the requirement to link clinical medications data and the data required for pharmacovigilance, regulation and supply chain. Following requests from SNOMED International Members and other stakeholders, SNOMED CT® has drafted a position statement describing the relationship between the proposed SNOMED CT Pharmaceutical/biologic product concept model and other international standards. Please click here to download the full document. This position statement is geared towards the following bodies for information and feedback as applicable: Policy makers, or equivalent agencies SNOMED International stakeholder groups Standards Development Organizations (SDOs) SNOMED CT® implementers and software vendors Pharmaceutical regulators and the pharmaceutical industry SNOMED International welcomes all opportunities to discuss partnerships in order to advance our drug content and quality for our members and stakeholders. For additional information, please contact info@snomed.org . Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

SNOMED International Welcomes Argentina as its 31st Member Back 7 Mar 2018 Back SNOMED International and the Ministerio de Salud are pleased to announce that Argentina has joined the organization as its thirty-first Member. As the newest SNOMED International Member, Argentina will leverage SNOMED CT’s structured clinical vocabulary to realize improvements in how clinical data is analyzed and reported on for the benefit of patient care. Argentina’s commitment to SNOMED CT sets the foundation for clinical data to be exchanged accurately and consistently across care settings, further extending the reach of structured clinical terminology throughout the Latin America region. SNOMED CT is the world’s most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization. The addition of Argentina has grown the organization’s Membership to thirty-one countries and territories across five continents, and enables Argentina to manage and use SNOMED CT and other related products, as well as participate on the organization’s General Assembly. “We are pleased to be welcoming Argentina as an official partner on this journey, formalizing a promising relationship that has existed for a number of years” said Don Sweete, SNOMED International CEO. “In Buenos Aires, private hospital entity, Hospital Italiano has been a long-term adopter of SNOMED CT. With Argentina’s Membership to SNOMED International, the Ministerio de Salud has crossed the threshold enabling Argentina to leverage SNOMED CT for the benefit of their healthcare system, affecting patients and providers alike.” Argentina has embarked on a national program to promote the development of a national health information infrastructure, supporting and guiding provincial governments projects for the adoption of a national interoperability framework. “The Ministerio de Salud and the Ministerio de Modernización of Argentina worked together to make this membership a reality; this will facilitate the adoption of SNOMED CT in health information implementations around the country. The Health Minister, Dr. Adolfo Rubinstein, defined that the National Health Information infrastructure is the foundation for the implementation of the Universal Health Coverage initiatives”, said Dr. Alejandro Lopez Osornio, responsible for the adoption of SNOMED CT in the Ministerio de salud. “Everything is already in place for provinces and providers to start requesting free licenses for the use of SNOMED CT, and we are planning a sequence of implementation support activities for the rest of the year.” Argentina becomes the third country in the Latin America region to join SNOMED International, positioning the region for increased interoperability as well as the promise of leveraging learnings amongst its regional and international counterparts. Through the next phase of their ehealth journey, Argentina has demonstrated their recognition of the value to the health system through investment in the world’s most comprehensive healthcare terminology product. Read the full press release . Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

Becoming a SNOMED International Member is the latest step for France to become a global leader in digital health. SNOMED International welcomes France as a new Member of the global SNOMED CT community Becoming a SNOMED International Member is the latest step for France to become a global leader in digital health. Back 24 Oct 2023 Back Becoming a SNOMED International Member is the latest step for France, a country of more than 67 million inhabitants, in its efforts to become a global leader in digital health. France will join a community of 48 Members globally. Its SNOMED International membership builds on the country’s eHealth acceleration strategy announced in January 2021. It also supports the “France relance ” recovery plan to accelerate the ecological, industrial and social transformations of the country, as well as the country’s 2023-2027 digital health roadmap , which seeks to employ digital technology to improve and transform its healthcare system. The French Agence du Numerique en Santé (ANS) will serve as the country’s National Release Centre for SNOMED CT. As a Member, France will also be represented on SNOMED International’s General Assembly and the organization’s Member Forum governance bodies. France is the 22nd of the 27 European Union (EU) countries to join SNOMED International. It is also the fourth following the announcement of EU funding for member countries wishing to adopt SNOMED CT, a comprehensive, multilingual healthcare terminology created for use by healthcare professionals to capture the care of individuals in an electronic health record and facilitate sharing, decision support and analytics, to support safe and effective health information exchange. Building on extensive translation efforts France will benefit from the extensive translation work already completed by the SNOMED International French Translation User Group . The group, which also includes members from Belgium , Canada , Switzerland and Luxembourg , released the first SNOMED CT common French translation in April 2020 as an option to be published as part of the national edition of any Member involved in producing the translation. This group has served as a model to other countries that share the same language and want to similarly develop translations of the terminology. « The development of interoperability is one of the priorities of the e-health French roadmap. Joining SNOMED International allows France to enhance its health and social Terminologies offer. Being a member also grants the French ecosystem the ability to join and collaborate with the SNOMED CT international community. » SNOMED International CEO Don Sweete concurs, adding that France’s membership will augment both the utility and reach of SNOMED CT across Europe. “France has clearly demonstrated its commitment to improving the health and welfare of its citizens through the application of digital health, and its decision to become a SNOMED International Member is an important step in that direction,” he says. “Although there have long been a number of affiliate license users in France, membership means the country can provide access to SNOMED CT – and its global community – to all its commercial and non-commercial users,” he adds. Media Inquiries Julie Messier Agence du Numérique en Santé Email: julie.messier@esante.gouv.fr Kelly Kuru SNOMED International Email: comms@snomed.org Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

IHE International Back IHE International Standards Partner In April 2019, IHE International and SNOMED International formally announced a license agreement encouraging data consistency and interoperability across international boundaries, with benefits for clinical care, research and operational efficiency. Additional information Through this agreement, the organizations have agreed on the production of a SNOMED CT IHE Set which includes a jointly decided upon set of SNOMED CT concepts and identifiers within IHE profiles. By placing the SNOMED CT codes referenced in IHE profiles under a free international license, the current agreement reduces incentives for national groups to specify variant code sets based on other terminologies. The SNOMED CT value sets specified in IHE profiles are selected to ensure data consistency and interoperability in support of a variety of clinical use cases. IHE profiles are developed in eleven active clinical and operational domains. SNOMED CT value sets referenced in these profiles are typically used to bind coded values to content in structured documents, discrete data elements and metadata. Approximately 30 IHE profiles reference SNOMED CT value sets as of the date of this agreement. Over the course of the 5 year agreement, the SNOMED CT IHE Set will be updated officially annually, taking into account updates to the IHE profiles which are performed annually in each IHE domain. Thirty-seven profiles within 6 domains currently fall within the scope of the agreement. Phast-Services, based in Paris, France, will serve as experts on behalf of IHE to maintain the SNOMED CT IHE Set. The IHE freeset is available as part of SNOMED International's Global Patient Set. The GPS is a managed collection of existing reference sets, available to any user at no cost. The GPS offers clinical content across dentistry, renal, family & general practice and nursing areas, and includes IHE , DICOM and HL7 International Patient Summary (IPS) domains and activities. Press Release: April 2019: SNOMED International and IHE International forge inaugural agreement jointly supporting optimal patient care Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

SNOMED CT MRCM - Beta Release Available Back 14 Feb 2017 Back Since the date of issue, this information is now out of date and has been archived. It has been made available for reference. The SNOMED CT MRCM represents the rules in the SNOMED CT concept model in a form that can be read by a computer and applied to test that concept definitions and expressions comply with these rules. The MRCM may be used for a variety of purposes, including the authoring and validation of SNOMED CT concepts, expressions, expression constraints and queries, natural language processing (NLP) and binding terminology to information models to support querying and interoperability. For more information about the MRCM, please visit http://snomed.org/mrcm. Members can download the MRCM Beta release package via the MLDS distribution site. Others may request access by contacting the Release Management Team by email ( info@snomed.org ), with the subject "Release Management Team - MRCM Beta access request". The SNOMED CT MRCM Beta release notes are available here. Please note that the Beta release package is distributed for evaluation purposes only. It must not be used in production clinical systems or in clinical settings. Subject to feedback on the Beta release, the MRCM data will be included in the July 2017 SNOMED CT International Release. To comment on the MRCM Beta release, please click on the Feedback button at the bottom of this MRCM page. All feedback must be submitted by Friday 31st March 2017. Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe

Diabetic patients require constant monitoring and foot screening on hospital admission by clinicians to identify injuries that might lead to infection and ulceration and to prevent progression of foot disease. Studies show that the correct management of diabetic foot patients (DFPs) in the UK could lead to a decrease in amputation rates, hospital admission avoidance, and a drastic reduction in the NHS cost of managing patients with diabetic foot problems1. The aim of this work is to develop and deploy a fully automated, API-based dashboard system that supports management of DFPs at Barts Health NHS Trust. Our algorithm extracts a list of patients from the Trust Data Warehouse who have been admitted to the hospital. For each patient, the free-text clinical notes created in the past 6 months are identified and processed with CLiX, a commercial natural language processing tool developed by Clinithink which uses post coordinated SNOMED-CT expressions to extract clinical terms from unstructured clinical notes. Demographic, clinical, and automated risk assessment data are presented in a secure and customizable dashboard. Preliminary results at the Royal London Hospital in east London showed that, in one month, the dashboard correctly identified 42 DFPs. Of these, 33 received an immediate clinical intervention and 9 had no recorded intervention. There were 7 incorrect identifications, mostly involving gestational diabetes, congenital conditions or non-diabetic patients. Our data-driven clinical tool continues to identify inpatients with diabetes and shows strong potential for improving early clinical intervention for DFPs. 1 - Guest JF et al., 2018. Back View Map Bart's Health NHS Trust (3 of 3) A SNOMED driven clinical dashboard system to support the identification and management of diabetic patients with possible foot disease in a large academic health system in east London Read More Country / Region EMEA Tags Artificial intelligence, Clinical Practice, Data analytics, Implementation, Research Diabetic patients require constant monitoring and foot screening on hospital admission by clinicians to identify injuries that might lead to infection and ulceration and to prevent progression of foot disease. Studies show that the correct management of diabetic foot patients (DFPs) in the UK could lead to a decrease in amputation rates, hospital admission avoidance, and a drastic reduction in the NHS cost of managing patients with diabetic foot problems1. The aim of this work is to develop and deploy a fully automated, API-based dashboard system that supports management of DFPs at Barts Health NHS Trust. Our algorithm extracts a list of patients from the Trust Data Warehouse who have been admitted to the hospital. For each patient, the free-text clinical notes created in the past 6 months are identified and processed with CLiX, a commercial natural language processing tool developed by Clinithink which uses post coordinated SNOMED-CT expressions to extract clinical terms from unstructured clinical notes. Demographic, clinical, and automated risk assessment data are presented in a secure and customizable dashboard. Preliminary results at the Royal London Hospital in east London showed that, in one month, the dashboard correctly identified 42 DFPs. Of these, 33 received an immediate clinical intervention and 9 had no recorded intervention. There were 7 incorrect identifications, mostly involving gestational diabetes, congenital conditions or non-diabetic patients. Our data-driven clinical tool continues to identify inpatients with diabetes and shows strong potential for improving early clinical intervention for DFPs. 1 - Guest JF et al., 2018. Description This project aims to develop a simple, user-friendly dashboard system to support clinicians at Barts Health NHS Trust in managing diabetic foot patients. The system helps identify patients who are currently in the Trust and highlights diabetic patients who may be at risk of developing foot infections or ulcers. The system extracts structured and free text information from patient EHRs, which are routinely exported from Oracle Millennium and stored in the Trust's Data Warehouse. The extracted notes are then sent to CLiX, a commercial natural language processing tool developed by Clinithink which uses SNOMED-CT to identify clinically relevant text and match to cohorts of interest. Patient clinical summaries with previously defined risk stratification obtained from CLIX are then displayed in easy-to-understand charts and tables that staff can personalise. By making it easier to spot issues early, the tool helps healthcare providers improve care, reduce the number of amputations, and save NHS resources. Scope SNOMED CT is a standardized terminology system able to identify and categorize clinical concepts and key terms related to diabetic foot disease. This not only improves the quality of data extracted from unstructured medical notes but also facilitates interoperability across different systems in healthcare. We used SNOMED CT because we wanted to extract granular, relevant clinical information consistently and comprehensively from clinical reports. By using SNOMED CT, we are able to align with national and international standards, making our solution scalable and adaptable to various clinical environments and a range of clinical conditions. How SNOMED CT will be used We used SNOMED CT Expression Constraint Language (ECL) to define cohorts of patients with diabetes and diabetic foot disease. These expressions are used by the CLiX NLP tool to identify and categorise relevant patients based on post coordinated SNOMED expressions extracted from unstructured clinical notes. Granular symptom information is automatically extracted by the NLP tool in SNOMED CT format. This level of detail allows us to * stratify patients based on their risk of developing diabetic foot disease, supporting early intervention and more personalised care pathways * generate a large SNOMED CT coded dataset used for analytics projects to better understand patients with diabetic foot disease in east London Finally, confirmed cases identified using the dashboard have the appropriate SNOMED CT code added to the patient's electronic care record by the clinical team. This ensures the information is available for future care and planning decisions, embedding the tool's outputs into routine clinical workflows. Why SNOMED CT will be used Contact More information Learn more Get SNOMED CT Information about our license and fee structure Learn more Learn more Explore the wide range of resources available to our community of practice Subscribe to SNOMED International news Stay up to date on SNOMED news, features, developments and newsletters by subscribing to our news service. Subscribe